Výsledky vyhledávání - Juan Martin‐Liberal

  • Zobrazuji výsledky 1 - 14 z 14
Upřesnit hledání
  1. 1
    Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

    Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity Autor Adrià Archilla‐Ortega, Carla Domuro, Juan Martín-Liberal, Purificacı́on Muñoz

    Vydáno 2022
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?

    Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? Autor Cinta Hierro, Ignacio Matos, Juan Martin‐Liberal, María Ochoa de Olza, Elena Garralda

    Vydáno 2019
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

    Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma Autor Stefan Diem, Benjamin Kasenda, Lavinia Spain, Juan Martín-Liberal, Riccardo Marconcini, Martin Gore, James Larkin

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience

    Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience Autor Marco Maruzzo, Juan Martín-Liberal, Christina Messiou, Aisha Miah, Khin Thway, Rolyn Alvarado, Ian Judson, Charlotte Benson

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)

    Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) Autor Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo, Nicolas Penel, Matthew Krebs, Roy S. Herbst, Richard A. Walgren, Ryan C. Widau, Gu Mi, Jin Jin, David Ferry, Ian Chau

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma

    Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma Autor Juan Martín-Liberal, Salma Alam, Anastasia Constantinidou, Cyril Fisher, Komel Khabra, Christina Messiou, David Olmos, Scott C. Mitchell, Omar Al‐Muderis, Aisha Miah, Mark Linch, Robin L. Jones, Michelle Scurr, Ian Judson, Charlotte Benson

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses

    Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses Autor Anna Morena D’Alise, Guido Leoni, Gabriella Cotugno, Loredana Siani, Rosa Vitale, Valentino Ruzza, Irene Garzia, Laura Antonucci, Elisa Micarelli, Veronica Venafra, Sven Gogov, Alessia Capone, Sarah Runswick, Juan Martín-Liberal, Emiliano Calvo, Víctor Moreno, Stefan N. Symeonides, Elisa Scarselli, Oliver Bechter

    Vydáno 2024
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors Autor Elizabeth J. Davis, Juan Martín-Liberal, Rebecca Kristeleit, Daniel C. Cho, Sarah P. Blagden, Dominik Berthold, Dana B. Cardin, María Vieito, Rowan Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E. Janik, Jason A. Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M. Mehnert

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor–naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A

    Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor–naive unresectable or me... Autor Helen Gogas, Andrew J.S. Furness, S. Thomas, Bernard Doger de Spéville Uribe, Y.K. Hong, Gino K. In, Donald P. Lawrence, A. García Castaño, Simon Haefliger, K. He, S. Lee, Juan Martín-Liberal, T. Medina, Friedrich Graf Finckenstein, Brian Gastman, Jeffrey Chou, Rana Fiaz, M. Catlett, G. Chen, Patrick Terheyden

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Autor Maria Lozano-Rabella, Andrea García-Garijo, Jara Palomero, Anna Yuste-Estevanez, Florian Erhard, Roc Farriol-Duran, Juan Martín-Liberal, Maria Ochoa de Olza, Ignacio Matos, Jared J. Gartner, Michael Ghosh, Francesc Canals, August Vidal, Josep M. Piulats, Xavier Matías‐Guiu, Irene Braña, Eva Muñoz‐Couselo, Elena Garralda, Andreas Schlösser, Alena Gros

    Vydáno 2023
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, n... Autor Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana‐Davila, Emiliano Calvo, Luis Paz‐Ares, Philippe A. Cassier, Johanna C. Bendell, Nicolas Penel, Matthew Krebs, Juan Martín-Liberal, Nicolás Isambert, A. Segado Soriano, Martin Wermke, Jennifer L. Cultrera, Ling Gao, Ryan C. Widau, Gu Mi, Jin Jin, David Ferry, Charles S. Fuchs, Daniel P. Petrylak, Ian Chau

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

    Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria Autor Ignacio Matos, Juan Martín-Liberal, Alonso García-Ruiz, Cinta Hierro, María Ochoa de Olza, Cristina Viaplana, Analía Azaro, María Vieito, Irene Braña, Gemma Mur, Javier Ros, José M. Mateos, Guillermo Villacampa, Roger Berché, Mafalda Oliveira, María Alsina, Elena Élez, Ana Oaknin, Eva Muñoz‐Couselo, Joan Carles, Enriqueta Felip, Jordi Rodón, Josep Tabernero, Rodrigo Dienstmann, Raquel Pérez-López, Elena Garralda

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors Autor Atish D. Choudhury, Celestia S. Higano, Johann S. de Bono, Natalie Cook, Dana E. Rathkopf, Kari B. Wisinski, Juan Martín-Liberal, Mark Linch, Elisabeth I. Heath, Richard D. Baird, Javier García-Carbacho, Miguel Quintela‐Fandino, Simon T. Barry, Elza C. de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G. Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I. Shapiro, Lillian L. Siu, Aaron R. Hansen

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

    Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours Autor Ignacio Melero, María de Miguel Luken, Guillermo de Velasco, Elena Garralda, Juan Martín-Liberal, Markus Joerger, Guzmán Alonso, Maria-Elisabeth Goebeler, Martin Schüler, David König, Reinhard Dummer, María Reig, Milton Ruiz, Emiliano Calvo, Jorge Esteban-Villarrubia, A. Oberoi, Paula Sàbat, J.J. Soto Castillo, Kira‐Lee Koster, Omar Saavedra, Cyrus Sayehli, Tanja Gromke, Heinz Läubli, Egle Ramelyte, Marta Fortuny, Ana Landa-Magdalena, Irene Moreno, Javier Torres-Jiménez, Alberto Hernando‐Calvo, Dagmar Hess, Fabricio Racca, Heike Richly, Andreas M. Schmitt, Corinne Eggenschwiler, Marco Sanduzzi‐Zamparelli, A. Vilalta, Jörg Trojan, Christine Koch, Peter R. Galle, Friedrich Foerster, Zlatko Trajanoski, Hubert Hackl, Falk Gogolla, Florestan Koll, Peter J. Wild, Felix K.‐H. Chun, Henning Reis, Peter Lloyd, Matthias Macháček, Thomas F. Gajewski, Wolf H. Fridman, Alexander M.M. Eggermont, Ralf C. Bargou, Sandra Schöniger, Josef Rüschoff, Anastasiia Tereshchenko, Carina Zink, Antonio da Silva, Felix S. Lichtenegger, Julia Akdemir, Manfred Rüdiger, Phil L'Huillier, Aradhana Dutta, Markus Haake, Alexandra Auckenthaler, Ana Gjorgjioska, Bernhard Rössler, Frank Hermann, Mara Liebig, Daniela Reichhardt, Christine Schuberth-Wagner, Jörg Wischhusen, Petra Fettes, Marlene Auer, Kathrin Klar, Eugen Leo

    Vydáno 2024
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: